[go: up one dir, main page]

IL319682A - Rna compositions targeting claudin-18.2 - Google Patents

Rna compositions targeting claudin-18.2

Info

Publication number
IL319682A
IL319682A IL319682A IL31968225A IL319682A IL 319682 A IL319682 A IL 319682A IL 319682 A IL319682 A IL 319682A IL 31968225 A IL31968225 A IL 31968225A IL 319682 A IL319682 A IL 319682A
Authority
IL
Israel
Prior art keywords
rna compositions
compositions targeting
targeting claudin
claudin
rna
Prior art date
Application number
IL319682A
Other languages
Hebrew (he)
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/077839 external-priority patent/WO2024074211A1/en
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of IL319682A publication Critical patent/IL319682A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL319682A 2022-10-06 2023-10-05 Rna compositions targeting claudin-18.2 IL319682A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2022/077839 WO2024074211A1 (en) 2022-10-06 2022-10-06 Rna compositions targeting claudin-18.2
EP2023051126 2023-01-18
PCT/EP2023/077618 WO2024074634A1 (en) 2022-10-06 2023-10-05 Rna compositions targeting claudin-18.2

Publications (1)

Publication Number Publication Date
IL319682A true IL319682A (en) 2025-05-01

Family

ID=88290638

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319682A IL319682A (en) 2022-10-06 2023-10-05 Rna compositions targeting claudin-18.2

Country Status (6)

Country Link
EP (1) EP4598954A1 (en)
JP (1) JP2025534447A (en)
CN (1) CN120129702A (en)
AU (1) AU2023357320A1 (en)
IL (1) IL319682A (en)
WO (1) WO2024074634A1 (en)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
EP1053023B2 (en) 1998-02-03 2011-03-30 Protiva Biotherapeutics Inc. Systemic delivery of serum stable plasmid lipid particles for cancer therapy
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
JP4951338B2 (en) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド Interfering RNA encapsulated in lipid
US6927663B2 (en) 2003-07-23 2005-08-09 Cardiac Pacemakers, Inc. Flyback transformer wire attach method to printed circuit board
JP4842821B2 (en) 2003-09-15 2011-12-21 プロチバ バイオセラピューティクス インコーポレイティッド Polyethylene glycol modified lipid compounds and uses thereof
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
EP1937213B1 (en) 2005-07-27 2017-10-25 Protiva Biotherapeutics Inc. Systems and methods for manufacturing liposomes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
JP5475753B2 (en) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド Lipid formulations for nucleic acid delivery
MX338780B (en) 2008-11-10 2016-05-02 Alnylam Pharmaceuticals Inc Novel lipids and compositions for the delivery of therapeutics.
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011066651A1 (en) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
EP2569276B1 (en) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
AU2012207606B2 (en) 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US8762704B2 (en) 2011-09-29 2014-06-24 Apple Inc. Customized content for electronic devices
EP2788006A1 (en) 2011-12-07 2014-10-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CA2856737C (en) 2011-12-07 2023-09-26 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
KR101890951B1 (en) 2012-12-20 2018-08-22 에스케이이노베이션 주식회사 Integrated Drying Gasification Process for Co-producing Synthesis Gas and High Quality of Coals
CN106795096B (en) 2014-06-25 2020-05-29 爱康泰生治疗公司 Novel lipid and lipid nanoparticle formulations for nucleic acid delivery
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
HRP20240865T1 (en) 2015-06-29 2024-10-11 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
SI3954225T1 (en) 2015-09-21 2024-03-29 Trilink Biotechnologies, Llc Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
AU2016343803B2 (en) 2015-10-28 2021-04-29 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
SMT202100681T1 (en) 2016-04-22 2022-01-10 BioNTech SE Methods for providing single-stranded rna
EP3532103B1 (en) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
BR112019017743A2 (en) * 2017-02-28 2020-04-07 Sanofi Sa therapeutic rna
WO2020041655A1 (en) * 2018-08-24 2020-02-27 Sanofi Therapeutic rna for solid tumor cancers
WO2021198157A1 (en) * 2020-03-30 2021-10-07 BioNTech SE Rna compositions targeting claudin-18.2
KR20230002571A (en) * 2020-04-14 2023-01-05 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Large sequence pan-coronavirus vaccine composition
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine

Also Published As

Publication number Publication date
CN120129702A (en) 2025-06-10
EP4598954A1 (en) 2025-08-13
AU2023357320A1 (en) 2025-04-17
JP2025534447A (en) 2025-10-15
WO2024074634A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
EP4045637A4 (en) Engineered muscle targeting compositions
IL299431A (en) Engineered muscle targeting compositions
WO2018191278A3 (en) Targeted compositions
IL292766A (en) Antibody-drug conjugates targeting claudin 18.2
EP1991248A4 (en) Antidepressant prodrugs
IL321083A (en) Advanced rna targeting (arnatar)
IL319682A (en) Rna compositions targeting claudin-18.2
CA3269729A1 (en) Rna compositions targeting claudin-18.2
WO2008107771A3 (en) 2',3'-di-o-acyl-5-fluoronucleosides
IL316630A (en) Rna compositions targeting hiv
HK40092141A (en) Antibody-drug conjugates targeting claudin 18.2
HK40123347A (en) Rna compositions targeting hiv
HK40087002A (en) Engineered muscle targeting compositions
HK40072861A (en) Engineered muscle targeting compositions
GB202216848D0 (en) Jackbag 2.0
GB202213970D0 (en) 5000%vv3davtripple4000x10,000xshohryakuvaixonevaivai137millioncirclexdotshohryakuvaizonevai Shohryakuvaizonevaivai13millioncirclexdotgagaligagaligalifaligalig
GB202213971D0 (en) 5000%vv3davtripple4000x10,000xshohryakuvai137millioncirclexdotshohryakuvaizonevai shohryakuvaizonevaivai13millioncircleexdotgagaligagaligaligaligaligalishohry
GB202213972D0 (en) 5000%vv3davtripple4000x10,000xshohryakuvaizonevaivai137millioncirclexdot shohryakuvaivai13millioncirclexdotgagaligagaligaligaligaligaalishohryakuvaishohryakuv
HK40117299A (en) Antibody-drug conjugate targeting claudin18.2
Pourgholam-Amiji et al. JSSA-Volume 13-Issue 4-Pages 1-92
CA3275761A1 (en) Advanced rna targeting (arnatar)
HK40118739A (en) Advanced rna targeting (arnatar)
CA3270378A1 (en) Compositions and methods for targeting, editing, or modifying genes
HK40111667A (en) Antisense oligonucleotides targeting unc13a
HK40106800A (en) Antisense oligonucleotides targeting actl6b